MolNFT v1 · #149167 · protein
Influenza B/MEMPHIS/13/03 endonuclease with I38T mutation with bound inhibitor, baloxavir acid (bxa)
6FS9 · Polymerase acidic protein: “Influenza B/MEMPHIS/13/03 endonuclease with I38T mutation with bound inhibitor, baloxavir acid (bxa)”. X-ray diffraction, 3 ligands (E4Z, MN, CL), 1 pocket (best druggability 0.56). MolNFT v1 #149167 on…
- PDB
- 6FS9
- Type
- protein
- Length
- 183 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Polymerase acidic protein
- EC
- 3.1.-.-
- UniProt
- Q5V8Z9
- Ligands
- E4Z, MN, CL
- Pockets
- 1 · best druggability 0.56
Structure
x-ray diffraction · 1 distinct chain · 49% helix, 16% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Polymerase acidic protein (EC 3.1.-.-) | protein | 183 | 49% helix, 16% strand | Q5V8Z9 |
Ligands and binding sites
- E4Z · Baloxavir acid · ligand · chains A
- MN · Manganese (II) ion · metal · 2 copies · chains A
- CL · Chloride ion · ion · 2 copies · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 290 | 0.56 | 0.76 | 34 | MN, E4Z, CL |
Compared structures
- 6FS9 · Influenza B/Memphis/13/03 endonuclease with I38T mutation with bound inhibitor, baloxavir… · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q5V8Z9
- Elsewhere: RCSB PDB 6FS9 · PDBe 6FS9 · UniProt Q5V8Z9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.